<SEC-DOCUMENT>0001019687-14-002113.txt : 20140523
<SEC-HEADER>0001019687-14-002113.hdr.sgml : 20140523
<ACCEPTANCE-DATETIME>20140523153614
ACCESSION NUMBER:		0001019687-14-002113
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20140519
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140523
DATE AS OF CHANGE:		20140523

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AETHLON MEDICAL INC
		CENTRAL INDEX KEY:			0000882291
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				133632859
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21846
		FILM NUMBER:		14867085

	BUSINESS ADDRESS:	
		STREET 1:		8910 UNIVERSITY CENTER LANE, SUITE 660
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122
		BUSINESS PHONE:		858-459-7800

	MAIL ADDRESS:	
		STREET 1:		8910 UNIVERSITY CENTER LANE, SUITE 660
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BISHOP EQUITIES INC
		DATE OF NAME CHANGE:	19930602
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>aethlon_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section&nbsp;13 or 15(d)&nbsp;of
the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
May 19, 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AETHLON MEDICAL, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <TD STYLE="width: 32%; font-size: 10pt">&nbsp;</td>
    <TD STYLE="width: 2%; font-size: 10pt">&nbsp;</td>
    <TD STYLE="width: 32%; font-size: 10pt">&nbsp;</td>
    <TD STYLE="width: 2%; font-size: 10pt">&nbsp;</td>
    <TD STYLE="width: 32%; font-size: 10pt">&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Nevada</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">of incorporation)</P></td>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</td>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">000-21846</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Commission File Number)</P></td>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</td>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">13-3632859</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(IRS Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification Number)</P></td></tr>
</table>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <TD STYLE="width: 55%; font-size: 10pt">&nbsp;</td>
    <TD STYLE="width: 3%; font-size: 10pt">&nbsp;</td>
    <TD STYLE="width: 42%; font-size: 10pt">&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">8910 University Center Lane, Suite 660</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">San Diego, California</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P></td>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</td>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">92122</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Zip Code)</P></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: (858) 459-7800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Not applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2 below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#111;</FONT>&nbsp;</FONT> &nbsp; <FONT STYLE="font-size: 10pt">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#111;</FONT>&nbsp;</FONT> &nbsp; <FONT STYLE="font-size: 10pt">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#111;</FONT>&nbsp;</FONT> &nbsp; <FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#111;</FONT>&nbsp;</FONT> &nbsp; <FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">FORWARD-LOOKING STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Form 8-K and other reports filed by
Registrant from time to time with the Securities and Exchange Commission (collectively, the &quot;Filings&quot;) contain or may
contain forward-looking statements and information that are based upon beliefs of, and information currently available to, Registrant's
management as well as estimates and assumptions made by Registrant's management. When used in the Filings the words &quot;anticipate,&rdquo;
&quot;believe,&quot; &quot;estimate,&quot; &quot;expect,&quot; &quot;future,&quot; &quot;intend,&quot; &quot;plan&quot; or the
negative of these terms and similar expressions as they relate to Registrant or Registrant's management identify forward-looking
statements. Such statements reflect the current view of Registrant with respect to future events and are subject to risks, uncertainties,
assumptions and other factors relating to Registrant's industry, Registrant's operations and results of operations and any businesses
that may be acquired by Registrant. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions
prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Although Registrant believes that the expectations
reflected in the forward-looking statements are reasonable, Registrant cannot guarantee future results, levels of activity, performance
or achievements. Except as required by applicable law, including the securities laws of the United States, Registrant does not
intend to update any of the forward-looking statements to conform these statements to actual results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 90px"><font style="font-size: 10pt"><b>ITEM 1.01</b></font></td>
    <td><font style="font-size: 10pt"><b>Entry into a Material Definitive Agreement</b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On May 19, 2014, Aethlon Medical, Inc. (&ldquo;Registrant&rdquo;
or the &ldquo;Company&rdquo;) entered into a definitive agreement (the &ldquo;Agreement&rdquo;) with Total Renal Research, Inc.,
dba DaVita Clinical Research (&ldquo;DCR&rdquo;). Pursuant to the Agreement, DCR will conduct site management administrative services
for a study site in connection with a planned clinical safety study of the Aethlon Hemopurifier&reg; in certain patients with Hepatitis-C
virus infection. The clinical trial is to be conducted at DaVita MedCenter Dialysis in Houston, Texas, and up to ten patients meeting
applicable eligibility requirements will be permitted to enroll in the study. The Principal Investigator for the study will be
Dr. Stephen Z. Fadem, who is co-medical director of DaVita MedCenter Dialysis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Agreement requires Registrant to pay
certain expenses related to the study projected to be less than $200,000, including certain start-up and close-out costs, patient
compensation and a project management fee to be paid to DCR calculated as five percent of total invoiced patient and site costs.
Registrant also will be responsible for the fees for any third-party consulting physicians, including Dr. Fadem, utilized in connection
with the study and other pass-through expenses if incurred. The Agreement is effective as of May 16, 2014 and will continue in
effect until completion of the services being provided by DCR pursuant to the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 90px"><font style="font-size: 10pt"><b>ITEM 8.01</b></font></td>
    <td><font style="font-size: 10pt"><b>Other Events</b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On May 20, 2014, Registrant disseminated
the Press Release attached to this Current Report as Exhibit 99.1, which announced, among other things, Registrant&rsquo;s entry
into the Agreement with DCR discussed above in Item 1.01.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On May 21, 2014, Registrant disseminated
the Press Release attached to this Current Report as Exhibit 99.2, which announced, among other things, high rapid virologic response
and sustained virologic response rates in Hepatitis-C virus infected individuals who were administered therapy with the Aethlon
Hemopurifier&reg;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The foregoing descriptions of the Press
Releases do not purport to be complete and are qualified in their entirety by the Press Releases attached as Exhibits 99.1 and
99.2 hereto. Readers should review the Press Releases for a complete understanding of their content and the matters announced and
described in the Press Releases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 90px"><font style="font-size: 10pt"><b>ITEM 9.01</b></font></td>
    <td><font style="font-size: 10pt"><b>Financial Statements and Exhibits</b></font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 12%; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 10pt">Exhibit No.</font></td>
    <td style="width: 88%; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 10pt">Description</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 10pt">99.1</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 10pt">Press Release dated May 20, 2014</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 10pt">99.2</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 10pt">Press Release dated May 21, 2014</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 46%">&nbsp;</td>
    <td style="width: 3%">&nbsp;</td>
    <td style="width: 48%"><font style="font-size: 10pt">&nbsp;AETHLON MEDICAL, INC.</font></td></tr>
<tr>
    <td style="vertical-align: top; border-bottom: white 3pt solid">&nbsp;</td>
    <td style="vertical-align: bottom; border-bottom: white 3pt solid">&nbsp;</td>
    <td style="vertical-align: top"></td>
    <td style="vertical-align: bottom; border-bottom: white 3pt solid">&nbsp;</td>
    <td style="vertical-align: top; border-bottom: white 3pt solid">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By:&nbsp;<u>/s/ James B. Frakes</u></P></td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">James B. Frakes</font></td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">Dated: May 23, 2014</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">Chief Financial Officer</font></td></tr>
</table>


<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>aethlon_ex9901.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 99.1</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="image_001.jpg" ALT="aethlon_logo" STYLE="height: 90px; width: 241px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Aethlon Medical<SUP>&reg;</SUP> Announces
Definitive Agreement with DaVita Clinical Research and Site Location and Principal Investigator of Hepatitis C Virus (HCV) Clinical
Study </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SAN DIEGO, May 20, 2014 /PRNewswire/ --
Aethlon Medical, Inc. (OTCQX:AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease,
cancer and other life-threatening conditions, announced today that it has entered into a definitive agreement with&nbsp;DaVita
Clinical Research<SUP>&nbsp;</SUP>(DCR) to provide clinical management services to support the forthcoming feasibility study of
the Aethlon Hemopurifier&reg;. The Hemopurifier is a first-in-class therapeutic device that targets the rapid elimination of circulating
viruses and tumor-secreted exosomes that suppress the immune system of cancer patients. Aethlon further announced that the Principal
Investigator for this study will be Dr. Stephen Z. Fadem.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The clinical trial site location will be
DaVita MedCenter Dialysis in Houston. Dr. Fadem is co-medical director of DaVita MedCenter Dialysis and this center is one of the
three largest dialysis centers in the country with 72 treatment stations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aethlon previously disclosed that the United
States Food and Drug Administration (FDA) had approved an Investigational Device Exemption (IDE) that allows the Company to initiate
human feasibility studies of the Aethlon Hemopurifier in the United States. Under the feasibility study protocol, Aethlon is to
treat ten ESRD patients infected with Hepatitis C virus (HCV) to demonstrate the safety of Hemopurifier therapy. Successful completion
of the feasibility study will set the stage for Aethlon to conduct pivotal studies required for market clearance to treat HCV and
potentially other disease indications.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&quot;The combination of DCR, DaVita MedCenter
Dialysis, and Dr. Fadem provides Aethlon with the ideal team of professionals and infrastructure with which to conduct our infectious
disease clinical study. Additionally, their proximity to M.D. Anderson Cancer Center and other specialty facilities located within
the Texas Medical Center provide for a unique location to conduct future clinical investigations of Hemopurifier&reg; therapy in
a variety of life-threatening health conditions,&rdquo; stated Aethlon Medical CEO Jim Joyce.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DCR is a specialty contract research organization
(CRO) with experience in conducting more than 300 early phase clinical trials. &nbsp;As a subsidiary of DaVita Healthcare Partners
Inc, DCR has access to one third of the total U.S. ESRD patient population and maintains a network that exceeds 150 investigative
physicians&rsquo; practices at more than 250 clinical sites.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Fadem is a practicing Houston nephrologist
and is currently the Chief Medical Officer at Kidney Associates, PLLC and the Medical Director for the Houston Kidney Center Integrated
Service Network at DaVita Kidney Care, a division of DaVita HealthCare Partners Inc. He began practice in 1978 after completing
a renal fellowship at The University of Texas Health Science Center in San Antonio. He is a graduate of the University of Oklahoma
College of Medicine, and did his internal medicine residency at The University of Texas and MD Anderson Hospital in Houston. He
is a Clinical Professor of Medicine at Baylor College of Medicine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">He is a Fellow of the American College
of Physicians, Fellow of the American Society of Nephrology, diplomat of the American Board of Quality Assurance and Utilization
Review Physicians (CHCQM - Certified Health Care Quality Management), and a member of the International Society of Nephrology,
Renal Physicians Association, the American Association of Kidney Patients and The National Kidney Foundation. He is active in
quality management, credentialing and peer review for his dialysis centers.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On a national level, he is co-chairman
of the Medical Advisory Board of the American Association of Kidney Patients, and a past vice-president of the Board of Directors.
He has also served on the Board of Directors of the Renal Physicians Association, and actively serves on two national RPA committees,
the Government Affairs Committee and the Health Finance Committee. Dr. Fadem has been active in the Forum of ESRD (end stage renal
disease) Networks and was a member of the CMS Clinical Performance Measures Committee. He lectures frequently on dialysis management,
preventive nephrology, vascular calcification, anemia, patient education, CKD education, computer technology and computer security.
Dr. Fadem is a co-editor of AAKP Renalife and is a reviewer for several peer reviewed journals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Fadem has been nationally recognized
by receiving the American Association of Kidney Patient's Nova Award, the National Kidney Foundation's Distinguished Service Award.
He has also received the National Kidney Foundation's Presidents Award and the Myron L. Jenkins Award. He has been awarded the
Peter Lundin Award for his contributions to patient education and The Visionary Award for his contributions to CKD education. He
is the 2013 winner of the DaVita Core Value Award for Continuous Improvement. He has been named as one of America's Top Doctors
by Castle Connolly and US News and World Report, and is consistently ranked as a Top Doctor in Houston by Texas Magazine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About DaVita Kidney Care</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DaVita Kidney Care&nbsp;is a division of DaVita HealthCare Partners
Inc., a Fortune 500&reg; company that, through its operating divisions, provides a variety of health care services to patient populations
throughout the United States and abroad. A leading provider of dialysis services in the United States, DaVita Kidney Care&nbsp;treats
patients with chronic kidney failure and end stage renal disease.&nbsp;DaVita Kidney Care&nbsp;strives to improve patients&rsquo;
quality of life by innovating clinical care, and by offering integrated treatment plans, personalized care teams and convenient
health-management services. As of March 31, 2014,&nbsp;DaVita Kidney Care&nbsp;operated or provided administrative services at
2,098 outpatient dialysis centers located in the United States serving approximately 165,000&nbsp;patients. The company also operated
75 outpatient dialysis centers located in 10 countries outside the United States.&nbsp;DaVita Kidney Care&nbsp;supports numerous
programs dedicated to creating positive, sustainable change in communities around the world. The company&rsquo;s leadership development
initiatives and social responsibility efforts have been recognized by Fortune, Modern Healthcare, Newsweek and WorldBlu. For more
information, please visit&nbsp;DaVita.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Aethlon Medical, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aethlon Medical creates innovative medical
devices to address life-threatening diseases. The Aethlon ADAPT&trade; (Adaptive Dialysis-like Affinity Platform Technology) establishes
the basis for a new class of therapeutics that target the rapid elimination of disease enabling particles from the circulatory
system of treated patients.&nbsp; The lead Aethlon ADAPT&trade; product is the Hemopurifier&reg;, a device that addresses a broad-spectrum
of viral pathogens as well as tumor-secreted exosomes that suppress the immune system of cancer patients.&nbsp; Aethlon is also
operating under two government contracts with the Defense Advanced Research Projects Agency (DARPA) related the development of
a medical device to reduce the incidence of sepsis. Exosome Sciences, Inc. is a majority owned Aethlon subsidiary that is advancing
exosome-based strategies to diagnose and monitor cancer and infectious disease progression.&nbsp; Additional information can be
found at www.AethlonMedical.com<FONT STYLE="color: blue"><U>.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: blue">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Certain statements herein may be forward-looking
and involve risks and uncertainties.&nbsp; Such forward-looking statements involve assumptions, known and unknown risks, uncertainties
and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different
from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks
and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA
will not approve the initiation of the Company's existing or future clinical programs or provide market clearance of the company's
products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT&trade; system or the Aethlon Hemopurifier&reg;
as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer
or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of
its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide
its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the
Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance,
competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result
of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors
detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or
revise any forward-looking statements, whether as a result of new information, future events, or otherwise.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Contacts:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">James A. Joyce<BR>
Chairman and CEO<BR>
858.459.7800 x301<BR>
jj@aethlonmedical.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jim Frakes<BR>
Chief Financial Officer<BR>
858.459.7800 x300<BR>
jfrakes@aethlonmedical.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Marc Robins<BR>
877.276.2467<BR>
mr@aethlonmedical.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>DaVita Media Contact:</B><BR>
Bianca Violante</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Office: 303.876.6614<BR>
Mobile: 443.417.6044<BR>
Bianca.Violante@DaVita.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SOURCE Aethlon Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>aethlon_ex9902.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 99.2</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="image_002.jpg" ALT="aethlon_logo" STYLE="height: 90px; width: 241px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Aethlon Medical<SUP>&reg;</SUP> Reports
Rapid and Sustained Virologic Response Rates in Hepatitis C (HCV) Treated Patients </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SAN DIEGO, May 21, 2014 /PRNewswire/ --
Aethlon Medical, Inc. (OTCQX:AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease,
cancer and other life-threatening conditions, today announced high rapid virologic response (RVR) and sustained virologic response
(SVR) rates in Hepatitis-C virus (HCV) infected individuals who were administered Hemopurifier&reg; therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Aethlon Hemopurifier&reg; is a first-in-class
medical device that selectively targets the rapid clearance of viral pathogens and tumor-secreted exosomes from the entire circulatory
system to improve the benefit of drug therapies administered to infectious disease and cancer patients. In HCV care, the device
is positioned to address drug resistance associated with emerging all-antiviral therapies and also targets to accelerate HCV RNA
depletion at the outset of peginterferon+ribavirin (PR) therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aethlon recently disclosed that the United
States Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE) that now allows the Company to initiate
HCV human feasibility studies of Hemopurifier&reg; therapy in the United States. Aethlon announced yesterday that its first U.S.
clinical study will be conducted at the DaVita MedCenter Dialysis in Houston, Texas. It is estimated that approximately 170 million
people worldwide are infected with HCV, which leads to chronic liver disease or cirrhosis, and is a leading cause of liver transplantation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the reported study, HCV-infected individuals
were enrolled to receive three six-hour Hemopurifier&reg; treatments during the first three days of a 48-week peginterferon+ribavirin
(PR) treatment regimen. The study was conducted under the leadership of Dr. Vijay Kher at the Medanta Medicity, a multi-specialty
medical institute established to be a premier center for medical tourism in India. Aethlon reported that Hemopurifier&reg; therapy
was well tolerated and without device-related adverse events in twelve treated patients.&nbsp; Of these twelve patients, nine completed
the Hemopurifier-PR treatment protocol, including seven genotype-1 patients and two genotype-3 patients. Seven of the nine patients
(n=7/9) achieved a sustained virologic response (SVR), which is the clinical definition of treatment cure and is defined as undetectable
HCV RNA 24-weeks after the completion of the 48-week PR drug regimen. Both genotype-3 patients achieved a SVR (n=2/2), while five
of the seven genotype-1 patients achieved a SVR (n=5/7)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Of the nine patients that completed the
protocol, five (n=5/9) also achieved a rapid virologic response (RVR), defined as undetectable HCV RNA at day 30 of therapy.&nbsp;
RVR represents the clinical endpoint that best predicts SVR cure rates. As a point of reference, the landmark IDEAL Study of 3,070
HCV genotype-1 patients documented that only 10.35% (n=318/3070) of PR treated patients will achieve a RVR.&nbsp; However, patients
that achieved a RVR had SVR rates of 86.2% (n=274/318) versus SVR rates of 32.5% (n=897/2752) in non-RVR patients.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Data from three patients were not included
in the reported dataset. Among the three patients was a genotype-5 patient who discontinued PR therapy at day 180, yet remained
undetectable at 1.5 years after initiation of therapy. The second was a genotype-3 patient who was unable to tolerate PR therapy
and, as a result, discontinued PR therapy at day-90, yet was still undetectable one year after initiating therapy. The third patient,
who had the genotype-1 virus, was reported undetectable at the completion of the 48-week PR treatment regimen, but SVR results
are not due on that patient until September of this year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&quot;It appears the intermittent application
of Hemopurifier&reg; therapy during just the first three days of a 48-week interferon regimen can significantly influence treatment
outcomes,&quot; stated Aethlon Chairman and CEO, Jim Joyce.&nbsp; &quot;We now look forward to the clinical advancement of Hemopurifier&reg;
protocols against infectious viral pathogens and cancer indications in the United States.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Aethlon Medical, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aethlon Medical creates innovative medical
devices to address life-threatening diseases. The Aethlon ADAPT&trade; (Adaptive Dialysis-like Affinity Platform Technology) establishes
the basis for a new class of therapeutics that target the rapid elimination of disease enabling particles from the circulatory
system of treated patients.&nbsp; The lead Aethlon ADAPT&trade; product is the Hemopurifier&reg;, a device that addresses a broad-spectrum
of viral pathogens as well as tumor-secreted exosomes that suppress the immune system of cancer patients.&nbsp; Aethlon is also
operating under two government contracts with the Defense Advanced Research Projects Agency (DARPA) related the development of
a medical device to reduce the incidence of sepsis. Exosome Sciences, Inc. is a majority owned Aethlon subsidiary that is advancing
exosome-based strategies to diagnose and monitor cancer and infectious disease progression.&nbsp; Additional information can be
found at <U>www.AethlonMedical.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: blue">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Certain statements herein may be forward-looking
and involve risks and uncertainties.&nbsp; Such forward-looking statements involve assumptions, known and unknown risks, uncertainties
and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different
from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks
and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA
will not approve the initiation of the Company's existing or future clinical programs or provide market clearance of the company's
products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT&trade; system or the Aethlon Hemopurifier&reg;
as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer
or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of
its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide
its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the
Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance,
competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result
of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors
detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or
revise any forward-looking statements, whether as a result of new information, future events, or otherwise.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Contacts:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">James A. Joyce<BR>
Chairman and CEO<BR>
858.459.7800 x301<BR>
jj@aethlonmedical.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jim Frakes<BR>
Chief Financial Officer<BR>
858.459.7800 x300<BR>
jfrakes@aethlonmedical.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Marc Robins<BR>
877.276.2467<BR>
mr@aethlonmedical.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SOURCE Aethlon Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0$`>`!X``#_VP!#``H'!PD'!@H)"`D+"PH,#QD0#PX.
M#QX6%Q(9)"`F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$!`)C!&2T4^2CD_0#W_
MVP!#`0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P``1"`!:`/$#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HI*X_Q3X]M]'9[
M33U6XO1PQ)^2(^_J?:M*=*=67+!79$YQ@KR.MGGBMHS)/(D<8ZL[``?B:Y^[
M\?:!:DK]L\YAVA0M^O2O)]2U:^U><RW]S),W8,?E7Z#H*IUZU+*H[U)?<<,\
M:_LH]6_X6=HF<>7>_7RA_C5VT\?:!=,%^V&$G_GLA4?GTKQRBM7E=%K1LA8R
MH?0<$\5S&)()$EC;HR,"#^(J6O`M.U6]TB<2V%S)`W<*?E;ZCH:]+\+>/8-7
M=+34`MO>'A2#\DI]O0^U>?B,OJ4ES1U1U4L5&;L]&=E12"EK@.H****`"BBB
M@`HHHH`****`"BBD)Q0`M%9VE^(-*UIY4TO4+:[:''F"&0-MSTS^1K1H`***
MSKWQ!I6FWT-E>ZA;P74^/*BD<!GR<#`^O%`&C124M`!1110`4444`%(:6JVH
M7D>G6$]W,<1PH7;WQVII7=D#=CE/'GBQM*@&G6+XO)ER[CK$G^)KRO.3DDDG
MG)JQ?WLVI7T]Y<',LSEV]O0?ATIMG:37]Y#:VR[YIF"J/>OIL-0CAZ?GU/&J
MU75G?[B&BO4K?X7Z4L""XN+J27'S,CA03[#%2_\`"L=%_P">E[_W]'^%8_VG
M0\S3ZG4/***]4E^&NA11L\D]VB*"69I0`!ZGBN!U_1DTF>*2TN4O-/N5WV]R
MC!@X[C(XR*UHXVE6ERQ>I%3#SIJ[,FBBBNLP/4_`7BMM4B_LZ_?-W"N8W)YE
M4>ON*[6OGZRO)M.O8;NW;;+"X=?\/QKW?3KV/4M/M[N'_5S(''MGM7SV8894
MI\T=F>IA:SG'E>Z+5%%%>>=8C,%4LQ``&23VKD;SXJ^$+)BK:PDK#M#&[C\P
M,5UDT2S1/&XRCJ589QP:Q[70_#OARU!BL=/LHD_Y:.JK^;'D_B:`*&D_$OPM
MK-PEO::K&)W.%CE1HRQ]`6`&?QKIW8(I9B%4#))/`KP;XP:WX8U,VD>ABWFO
MXW+37-LH"[<?=+#ACG!]L>]=AXLUF>3P_H.FFX,?VRVBEN96/4%5'/MG)/TK
M6C2=6:@B*D^2/,=5/X[\/V\IC;4$9@>3&C,!^(&*U--UBPUB(R:?=1SJ.NT\
MCZCJ*PM,U+PCI-FEM:WM@%`PS$@L_N3WKE]1O].T[QSI]]X>N(6CG8+.D)^7
MEL$8]P<_45T+#QG>,4UYOK^&A@ZSC9MI^A2\6_$\#QKI$.CZVHT<.GVTQIQQ
M)\P)(SC:!TKT31_&6@^(;M[72=2BN9T0R%%#`A00,\CU(KRSQ_H>EV7Q5\-V
MEKI]K%;7!B,T21`+)F4@[AWR*];T[PWHVCSM/INEV=I,RE"\,*H2O7&1VX%<
M1U'DOP/N[>PNO$ES=S1P01I$7DD8*JC<_4FNZD^+O@Z.?RO[5+<X+K!(5_/%
M>2?#'PNOBOQ%=VMX\G]EPXGN8D8J)F!(121]6/X&O;I?`/AB:R-JVA6`C(Q\
ML(5A[AASGWS0!IZ5K6GZY:"ZTN[BNH"<;XVS@^A'4'V->3_%+_DK/A?_`+8?
M^CC4/PS@?PY\6M8T*WF=[0)(N">NU@5)]P"1^)J;XI?\E9\+_P#;#_T<:`/9
M:Y75/B;X4TB=H+C5HWE0X985:3!^J@C]:POC1XFN=%\/6^GV,C1SZD[(S+U$
M:@;@#[D@?3-:_A#X<Z+X?T>!9K"WNKYHP9YYHPY+'D@9Z`>U`&EH7CCP]XDE
M\G2]3BEGQGRF!1S]`P!/X5L7=[!86<UW=2"*WA0O(YZ*HY)KS#XJ>!+"TT1_
M$.AVZ6%]8NLCFW&P.NX#.!T8$@Y'O6PFOOXE^"UYJ4V//?3YDFP/XU!4G\<9
M_&@#HH_&GA^31FU5=4MQ8*YC,S$J-P_A`/)//85CQ_%WP=)/Y7]JE><;V@D"
M_GBO//A%X/@\3VLMWK0:XT^QE*6]JQ.PR,`68COQM_R*].UCX<^&]6TV2U_L
MFSMV*%8YH(@CQGL01_(T`=%9WMOJ%I'=6<\<]O(-R21L&5A[$5RWQ,O3;^&E
M@4X-S,J'_=')_D*X_P"`E].8=9TUW+0P/'(@SPI;<#CZ[16_\5R?LVF#MYDG
M\A73@XJ5>*9CB':DSSBO1/AGH.%DUB=>6S';Y]/XF_I^=<3HVERZSJL%C#P9
M6^9O[J]S^5>YV=K%96D5M;H$BB0(@'8"O3S+$<L?9K=_D<6#I<TN=[(F%+15
M;4;^#2]/N+V[D$<%NADD;T`&:\,],\W^-?BW^R]%30[63%S?C,V#RL([?\"/
M'T!K@OA[J*ZG:77A>X;YILW&GLQ^Y,!RGL&'ZCWKEO$VOS^)O$%WJESD-._R
M(3G8@X5?P%4+2YEL[N*YMY#'-"X>-UZJP.0:J$G"2E'=$RBI*S._(*L58%6!
MP0>QI*U-4FBUFPM/$5HH6._&VY1>D5POWQ^/WA]:RZ^JHU55@IKJ>+4@X2<6
M%>K?#*\-QX<>W8Y-M,RC_=/(_F:\IKT;X4$^3J@SQNC/Z-7+F44Z#?:QMA':
MJCT*BBBOG3UCD/B=XGN_"GA![S3\"ZFE6!'(SY>026QW.%-<QX2^&5OX@TVU
MUSQ9>W>IW-V@F6)ICL16Y`)ZDX],"N^\5>&[7Q9H4VEWI94DPR2+]Z-QT8?Y
MZ$UQ>D^#/'OAVT%AI?B6P>RCR(A/"6*#VR#CZ9Q0!F_&70]-T/P/90Z78V]H
MAOER(D`+?(_4]3^-6/$40M8?">HSQA[86D*.&&1P`2#^!/Y5K^(/`.L>*/!]
MKIFK:U')?QW1N)+CR?D(PP"J!C``(KIW\/6UUX;M](OAYJ10I'O7@[E4#</0
M\5MAZJI5%)[&56#G"R)(]%T::-9(].L61@&5A"N"#^%2+H>E(ZLFFVBLIR"(
M5!!_*N8M_"?B/2%,.D:\@M1]U)X\[?IP:T-*T'78]3BN]7UHW*1Y(@C7:I)&
M`3T_E5SBDFU4O]]R8N^CA^1POQ)('Q@\*$D`?N>3_P!=C7L!-<'\1/AS+XRG
MM+ZQO5M+ZV78"X.UESD<CD$'/YU8\(>&_%>F:FUQXB\0C4+<0E$@3.`Q(^8Y
M`S@`_G7,;G&?`3_D)^(/I%_Z$]>SUQ'P]^'LW@F[U&:6_CNA>!``L93;@L?4
M_P!ZNW-`'C7A;_DX+6?^VW_LM'Q2_P"2L^%_^V'_`*.-=?I/P_FTWXC7OB9K
M^-X[GS,0",@KNQWS[4>+/A_-XD\8:5K4=_'`EAY>8FC+%]KENN>.N*`.:^/%
MG,MOHNJ1J6CMIG1^.`3M*Y_[Y->H:7J4&K:7;7]JX>&XC$BL/<?Y%)JVDVFN
M:7/I^HPB:VG7:RG]"#V(Z@UYU;?#7Q3X;E>/PKXI$5DS%A#<IG;^&"#]0!0!
MN_%K5+?3OA_J$<S#S+L+!$F>6)()_(`FL/PYILNF_`.\$RE7N+.XGVGL&!V_
MH`?QI]K\*+_5M5BO_&NN/JAA/R6Z9"?3)Q@>H`&?6N\UO2O[5\/7NF1,L'VF
MW:%6VY"9&!QZ"@#BO@8!_P`($_\`U^R?^@K7HQZ&N:\`^$Y/!GAYM-ENDN6,
M[2[U3:.0!C&3Z5TIZ4`>+_`3_D)^(/I%_P"A/79?%*U,FAVMP/\`EC/@^P88
M_F!3?A[\/9O!-UJ,TM_'=?;`@`6,KMVECZG^]76:MID&L:=)970)BDQNQUX.
M?Z5K0J>RJ1GV,ZL.>#B<M\-]!^QZ:VISIB>Z&(\]5C_^N>?RKM:;&BQ(J(H5
M%`"@=`!3Z5:JZLW-]1TX*$5%"&O./BMJRW-E_8$;X\X![@@]!U4?F,_@*[S5
MM1ATG39[VX/[N%2V.Y/8#ZFO"KV]FU&^FN[ALRS.7;_#\.E=N7X959N<EHCG
MQ5;D2C'=GG,\+V\SQ2##H<$5%72>)K#(6\C'(^63'Z&N<KEQ-%T:CB;TJBJ0
M4D=I\.=6B^V7'A^^D"VFJ@+&YZ17`_U;?C]T_45ISP26MQ)!.I26)BCJ>Q'6
MO.48HP96((Y!'45ZI+>CQ-X=M/$"$&Z7%KJ*CM*!\LG_``(?K79EN(Y)^SEL
M_P`SFQE*\>==#-KU#X6VQCT:[N#TFGP/HH_Q)KS!59W5$4L[$*JCJ2>E>Z>'
MM+&C:%:67&^-/G/JQY/ZFNO-*BC24._Z&&#C>?-V-.BBBO!/4"BBB@`I*6B@
M!,44M%`!36.%)]!3J:XRI`ZD4`<MI7C5;_1M1O;BW$#V8W>6'SO4CY3G'<\5
M$OC6Y?0;6^6P03W%Y]E\EIL!3SR6Q[53A\&WX;258QK"$6._0-]X(Y=<>O7%
M/NO"VHR:'%;"""61-3>Z:-I,*T9).,^^:[^7#W]7^']:G)S5K&K=^(-1T[0[
MW4+ZQME-OMV)%<[P^3@Y..,9I/\`A(]0LKFT76-,CM[>Z<1)/#/Y@5CTW#`Q
MFJEWHE[>>%]1T^#2;33Y)BAC6*8%7.022<#'2I9]-UG7)K&'48+:SL;65)G"
M2^8\K+T'08%9J-.VMNO7R5K:E-SOI<E;QBD%GJEQ<6[#[%=?98T1LF5NWTS6
MAIMWK,\X_M#3[>W@92<I/O93V!&*PI/"=Y=6>KQO)'#--J'VRU?.1D=-U7YK
MGQ-/83PC3;:&X,159EN<@N>,@8X'4\TIQIM6A;[_`$'&4]Y7&VOBX7/B#[%]
MFVV<DCPPW6[B21`"5Q^?Y5?TK6FU+5-4M#"(Q8RK&&#9WY&<^U8%QX$6VT2W
M.F,XU6V*2([S-L9P06X/`SSVJQ96FNZ7J^J74&G6\Z7TBR`-<[2N%QCH>].4
M*,D^1_\`#W_5"C*HFN8ZVL>YUQ[?Q$FF"`,K6C7'F;N<@XQBK&FW]Q?378EM
M&@C@D\M'8_ZP@?,0,=,\9[U0O-(NIO%L>H(J?9Q8O`26YW$Y'%8PC%-J?8UE
M)M)Q*NB>-!JVF7LTEMY%U;0F<0ELB1,$A@<=,C%2R>*9G&FP6-EY]_?6XN/+
M,FU(DQU9L?TK+E\(7X\+V"VICBU>TB:%OF^61&)W(3]#FKG]@ZGI\NEZAIZP
M275M9K:W%O(^T2*/1O4&NAQH7;CY_P!>ABG5MJ=#IDM]+`QU&WB@E#8`BDWJ
M1ZYP*MFLE+K6GLU<Z=;Q3F95,37&X"/NV0.OM5G6+R:PTFYN;:!YYHT)2-!D
MD]N*Y7%N5C=221Y]\2M>^TWJ:3`^8K<[YL=W[#\!_.N&I\TLDT\DDS%I78LY
M;J6/6F5]1AZ2HTU!'CU)NI)R8V6))XGBD&4<8(KA;VU:SNY('ZJ>#ZCL:[RH
MI;6"=MTT,;MC&64&L,9A%B$K.S1IAZ_LF[['`XKJ?`.NPZ3K36FH-_Q+-23[
M-<YZ)D_*_P!5//TS6E_9]GD#[)!D]!Y8KM?"OPPBOW2[U>RBAM1\RPE`'D^O
MH/UKS*N!=!<TII'9#$JJ^51-7P7X+GMM:EO-3CPEI(4A!'$C#^,>WI_]:O1<
M4V*-8HT2-0J(`JJ.@`Z4^N2M7E6ES2-Z=.-.-D%%%%8F@4444`%%%%`!1110
M`4F*6B@!,48I:*`$Q1BEHH`3%&*6B@!,48I:*`$`Q12T4`)BC%+10`F*,4M%
M`&)K'A'2-:)>YM0LQ_Y;1':_X^OXUREW\*CN)LM2X_NS1_U'^%>BFBMZ>+K4
MM(R,IT*<]T>6_P#"K=5S_P`?EECZM_A5VU^%3;@;W4AC^[#'S^9/]*]%HK5Y
MCB'I<A86DNABZ/X1TC12'MK4-,/^6TIW-^'I^%;6**6N64Y3=Y.[-XQ459(*
****D84444`?_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X``02D9)1@`!`0$`>`!X``#_VP!#``H'!PD'!@H)"`D+"PH,#QD0#PX.
M#QX6%Q(9)"`F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$!`)C!&2T4^2CD_0#W_
MVP!#`0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P``1"`!:`/$#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HI*X_Q3X]M]'9[
M33U6XO1PQ)^2(^_J?:M*=*=67+!79$YQ@KR.MGGBMHS)/(D<8ZL[``?B:Y^[
M\?:!:DK]L\YAVA0M^O2O)]2U:^U><RW]S),W8,?E7Z#H*IUZU+*H[U)?<<,\
M:_LH]6_X6=HF<>7>_7RA_C5VT\?:!=,%^V&$G_GLA4?GTKQRBM7E=%K1LA8R
MH?0<$\5S&)()$EC;HR,"#^(J6O`M.U6]TB<2V%S)`W<*?E;ZCH:]+\+>/8-7
M=+34`MO>'A2#\DI]O0^U>?B,OJ4ES1U1U4L5&;L]&=E12"EK@.H****`"BBB
M@`HHHH`****`"BBD)Q0`M%9VE^(-*UIY4TO4+:[:''F"&0-MSTS^1K1H`***
MSKWQ!I6FWT-E>ZA;P74^/*BD<!GR<#`^O%`&C124M`!1110`4444`%(:6JVH
M7D>G6$]W,<1PH7;WQVII7=D#=CE/'GBQM*@&G6+XO)ER[CK$G^)KRO.3DDDG
MG)JQ?WLVI7T]Y<',LSEV]O0?ATIMG:37]Y#:VR[YIF"J/>OIL-0CAZ?GU/&J
MU75G?[B&BO4K?X7Z4L""XN+J27'S,CA03[#%2_\`"L=%_P">E[_W]'^%8_VG
M0\S3ZG4/***]4E^&NA11L\D]VB*"69I0`!ZGBN!U_1DTF>*2TN4O-/N5WV]R
MC!@X[C(XR*UHXVE6ERQ>I%3#SIJ[,FBBBNLP/4_`7BMM4B_LZ_?-W"N8W)YE
M4>ON*[6OGZRO)M.O8;NW;;+"X=?\/QKW?3KV/4M/M[N'_5S(''MGM7SV8894
MI\T=F>IA:SG'E>Z+5%%%>>=8C,%4LQ``&23VKD;SXJ^$+)BK:PDK#M#&[C\P
M,5UDT2S1/&XRCJ589QP:Q[70_#OARU!BL=/LHD_Y:.JK^;'D_B:`*&D_$OPM
MK-PEO::K&)W.%CE1HRQ]`6`&?QKIW8(I9B%4#))/`KP;XP:WX8U,VD>ABWFO
MXW+37-LH"[<?=+#ACG!]L>]=AXLUF>3P_H.FFX,?VRVBEN96/4%5'/MG)/TK
M6C2=6:@B*D^2/,=5/X[\/V\IC;4$9@>3&C,!^(&*U--UBPUB(R:?=1SJ.NT\
MCZCJ*PM,U+PCI-FEM:WM@%`PS$@L_N3WKE]1O].T[QSI]]X>N(6CG8+.D)^7
MEL$8]P<_45T+#QG>,4UYOK^&A@ZSC9MI^A2\6_$\#QKI$.CZVHT<.GVTQIQQ
M)\P)(SC:!TKT31_&6@^(;M[72=2BN9T0R%%#`A00,\CU(KRSQ_H>EV7Q5\-V
MEKI]K%;7!B,T21`+)F4@[AWR*];T[PWHVCSM/INEV=I,RE"\,*H2O7&1VX%<
M1U'DOP/N[>PNO$ES=S1P01I$7DD8*JC<_4FNZD^+O@Z.?RO[5+<X+K!(5_/%
M>2?#'PNOBOQ%=VMX\G]EPXGN8D8J)F!(121]6/X&O;I?`/AB:R-JVA6`C(Q\
ML(5A[AASGWS0!IZ5K6GZY:"ZTN[BNH"<;XVS@^A'4'V->3_%+_DK/A?_`+8?
M^CC4/PS@?PY\6M8T*WF=[0)(N">NU@5)]P"1^)J;XI?\E9\+_P#;#_T<:`/9
M:Y75/B;X4TB=H+C5HWE0X985:3!^J@C]:POC1XFN=%\/6^GV,C1SZD[(S+U$
M:@;@#[D@?3-:_A#X<Z+X?T>!9K"WNKYHP9YYHPY+'D@9Z`>U`&EH7CCP]XDE
M\G2]3BEGQGRF!1S]`P!/X5L7=[!86<UW=2"*WA0O(YZ*HY)KS#XJ>!+"TT1_
M$.AVZ6%]8NLCFW&P.NX#.!T8$@Y'O6PFOOXE^"UYJ4V//?3YDFP/XU!4G\<9
M_&@#HH_&GA^31FU5=4MQ8*YC,S$J-P_A`/)//85CQ_%WP=)/Y7]JE><;V@D"
M_GBO//A%X/@\3VLMWK0:XT^QE*6]JQ.PR,`68COQM_R*].UCX<^&]6TV2U_L
MFSMV*%8YH(@CQGL01_(T`=%9WMOJ%I'=6<\<]O(-R21L&5A[$5RWQ,O3;^&E
M@4X-S,J'_=')_D*X_P"`E].8=9TUW+0P/'(@SPI;<#CZ[16_\5R?LVF#MYDG
M\A73@XJ5>*9CB':DSSBO1/AGH.%DUB=>6S';Y]/XF_I^=<3HVERZSJL%C#P9
M6^9O[J]S^5>YV=K%96D5M;H$BB0(@'8"O3S+$<L?9K=_D<6#I<TN=[(F%+15
M;4;^#2]/N+V[D$<%NADD;T`&:\,],\W^-?BW^R]%30[63%S?C,V#RL([?\"/
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MUSQ9>W>IW-V@F6)ICL16Y`)ZDX],"N^\5>&[7Q9H4VEWI94DPR2+]Z-QT8?Y
MZ$UQ>D^#/'OAVT%AI?B6P>RCR(A/"6*#VR#CZ9Q0!F_&70]-T/P/90Z78V]H
MAOER(D`+?(_4]3^-6/$40M8?">HSQA[86D*.&&1P`2#^!/Y5K^(/`.L>*/!]
MKIFK:U')?QW1N)+CR?D(PP"J!C``(KIW\/6UUX;M](OAYJ10I'O7@[E4#</0
M\5MAZJI5%)[&56#G"R)(]%T::-9(].L61@&5A"N"#^%2+H>E(ZLFFVBLIR"(
M5!!_*N8M_"?B/2%,.D:\@M1]U)X\[?IP:T-*T'78]3BN]7UHW*1Y(@C7:I)&
M`3T_E5SBDFU4O]]R8N^CA^1POQ)('Q@\*$D`?N>3_P!=C7L!-<'\1/AS+XRG
MM+ZQO5M+ZV78"X.UESD<CD$'/YU8\(>&_%>F:FUQXB\0C4+<0E$@3.`Q(^8Y
M`S@`_G7,;G&?`3_D)^(/I%_Z$]>SUQ'P]^'LW@F[U&:6_CNA>!``L93;@L?4
M_P!ZNW-`'C7A;_DX+6?^VW_LM'Q2_P"2L^%_^V'_`*.-=?I/P_FTWXC7OB9K
M^-X[GS,0",@KNQWS[4>+/A_-XD\8:5K4=_'`EAY>8FC+%]KENN>.N*`.:^/%
MG,MOHNJ1J6CMIG1^.`3M*Y_[Y->H:7J4&K:7;7]JX>&XC$BL/<?Y%)JVDVFN
M:7/I^HPB:VG7:RG]"#V(Z@UYU;?#7Q3X;E>/PKXI$5DS%A#<IG;^&"#]0!0!
MN_%K5+?3OA_J$<S#S+L+!$F>6)()_(`FL/PYILNF_`.\$RE7N+.XGVGL&!V_
MH`?QI]K\*+_5M5BO_&NN/JAA/R6Z9"?3)Q@>H`&?6N\UO2O[5\/7NF1,L'VF
MW:%6VY"9&!QZ"@#BO@8!_P`($_\`U^R?^@K7HQZ&N:\`^$Y/!GAYM-ENDN6,
M[2[U3:.0!C&3Z5TIZ4`>+_`3_D)^(/I%_P"A/79?%*U,FAVMP/\`EC/@^P88
M_F!3?A[\/9O!-UJ,TM_'=?;`@`6,KMVECZG^]76:MID&L:=)970)BDQNQUX.
M?Z5K0J>RJ1GV,ZL.>#B<M\-]!^QZ:VISIB>Z&(\]5C_^N>?RKM:;&BQ(J(H5
M%`"@=`!3Z5:JZLW-]1TX*$5%"&O./BMJRW-E_8$;X\X![@@]!U4?F,_@*[S5
MM1ATG39[VX/[N%2V.Y/8#ZFO"KV]FU&^FN[ALRS.7;_#\.E=N7X959N<EHCG
MQ5;D2C'=GG,\+V\SQ2##H<$5%72>)K#(6\C'(^63'Z&N<KEQ-%T:CB;TJBJ0
M4D=I\.=6B^V7'A^^D"VFJ@+&YZ17`_U;?C]T_45ISP26MQ)!.I26)BCJ>Q'6
MO.48HP96((Y!'45ZI+>CQ-X=M/$"$&Z7%KJ*CM*!\LG_``(?K79EN(Y)^SEL
M_P`SFQE*\>==#-KU#X6VQCT:[N#TFGP/HH_Q)KS!59W5$4L[$*JCJ2>E>Z>'
MM+&C:%:67&^-/G/JQY/ZFNO-*BC24._Z&&#C>?-V-.BBBO!/4"BBB@`I*6B@
M!,44M%`!36.%)]!3J:XRI`ZD4`<MI7C5;_1M1O;BW$#V8W>6'SO4CY3G'<\5
M$OC6Y?0;6^6P03W%Y]E\EIL!3SR6Q[53A\&WX;258QK"$6._0-]X(Y=<>O7%
M/NO"VHR:'%;"""61-3>Z:-I,*T9).,^^:[^7#W]7^']:G)S5K&K=^(-1T[0[
MW4+ZQME-OMV)%<[P^3@Y..,9I/\`A(]0LKFT76-,CM[>Z<1)/#/Y@5CTW#`Q
MFJEWHE[>>%]1T^#2;33Y)BAC6*8%7.022<#'2I9]-UG7)K&'48+:SL;65)G"
M2^8\K+T'08%9J-.VMNO7R5K:E-SOI<E;QBD%GJEQ<6[#[%=?98T1LF5NWTS6
MAIMWK,\X_M#3[>W@92<I/O93V!&*PI/"=Y=6>KQO)'#--J'VRU?.1D=-U7YK
MGQ-/83PC3;:&X,159EN<@N>,@8X'4\TIQIM6A;[_`$'&4]Y7&VOBX7/B#[%]
MFVV<DCPPW6[B21`"5Q^?Y5?TK6FU+5-4M#"(Q8RK&&#9WY&<^U8%QX$6VT2W
M.F,XU6V*2([S-L9P06X/`SSVJQ96FNZ7J^J74&G6\Z7TBR`-<[2N%QCH>].4
M*,D^1_\`#W_5"C*HFN8ZVL>YUQ[?Q$FF"`,K6C7'F;N<@XQBK&FW]Q?378EM
M&@C@D\M'8_ZP@?,0,=,\9[U0O-(NIO%L>H(J?9Q8O`26YW$Y'%8PC%-J?8UE
M)M)Q*NB>-!JVF7LTEMY%U;0F<0ELB1,$A@<=,C%2R>*9G&FP6-EY]_?6XN/+
M,FU(DQU9L?TK+E\(7X\+V"VICBU>TB:%OF^61&)W(3]#FKG]@ZGI\NEZAIZP
M275M9K:W%O(^T2*/1O4&NAQH7;CY_P!>ABG5MJ=#IDM]+`QU&WB@E#8`BDWJ
M1ZYP*MFLE+K6GLU<Z=;Q3F95,37&X"/NV0.OM5G6+R:PTFYN;:!YYHT)2-!D
MD]N*Y7%N5C=221Y]\2M>^TWJ:3`^8K<[YL=W[#\!_.N&I\TLDT\DDS%I78LY
M;J6/6F5]1AZ2HTU!'CU)NI)R8V6))XGBD&4<8(KA;VU:SNY('ZJ>#ZCL:[RH
MI;6"=MTT,;MC&64&L,9A%B$K.S1IAZ_LF[['`XKJ?`.NPZ3K36FH-_Q+-23[
M-<YZ)D_*_P!5//TS6E_9]GD#[)!D]!Y8KM?"OPPBOW2[U>RBAM1\RPE`'D^O
MH/UKS*N!=!<TII'9#$JJ^51-7P7X+GMM:EO-3CPEI(4A!'$C#^,>WI_]:O1<
M4V*-8HT2-0J(`JJ.@`Z4^N2M7E6ES2-Z=.-.-D%%%%8F@4444`%%%%`!1110
M`4F*6B@!,48I:*`$Q1BEHH`3%&*6B@!,48I:*`$`Q12T4`)BC%+10`F*,4M%
M`&)K'A'2-:)>YM0LQ_Y;1':_X^OXUREW\*CN)LM2X_NS1_U'^%>BFBMZ>+K4
MM(R,IT*<]T>6_P#"K=5S_P`?EECZM_A5VU^%3;@;W4AC^[#'S^9/]*]%HK5Y
MCB'I<A86DNABZ/X1TC12'MK4-,/^6TIW-^'I^%;6**6N64Y3=Y.[-XQ459(*
****D84444`?_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
